New targeted therapies reduce waste and identify patients that will benefit most, but their high price tags have left the healthcare industry scrambling to figure out how to pay for these treatments and cures.
The creation and implementation of a new quality measure is a long process that includes considering other measures on the market, actually developing the measure and, ultimately, testing its scientific acceptability, explained Matthew Pickering, PharmD, RPh, associate director of research and quality strategies at the Pharmacy Quality Alliance.
A study published in the journal Cancer has found that the rate of advanced imaging at the time of breast cancer diagnosis reduced during the period between 2008 and 2015 in the state of Michigan.
A provision in President Donald Trump’s budget proposal would incorporate the Agency for Healthcare Research and Quality (AHRQ) within the National Institutes of Health (NIH), which could represent a threat or an opportunity.
In a session covering the future of the business of healthcare in the United States, Kevin Grabenstatter, managing director for L.E.K. Consulting, asserted that healthcare is an unsustainably big business, which means that change is coming.
Many women with breast cancer turn to radiotherapy, a proven treatment that reduces the risks of recurrence and death. However, long-term smokers face a greater risk of lung cancer and cardiac mortality from radiotherapy.
There is a trend of making value-based deals to pay for treatments in order to ensure the drug works as advertised while also protecting payers from financial risk, explained Richard J. Willke, PhD, chief science officer of ISPOR.
Clinical Pathways Compendium
COPD Compendium
Diabetes Compendium
GI Compendium
Lipids Compendium
MACRA Compendium
Oncology Compendium
Rare Disease Compendium
Reimbursement Compendium
Know Your News
HF Compendium